Skip to main content

Table 1 Basic characteristics of the 9,528 patients who underwent an initial IVF/ICSI cycle

From: Influence of endometrial thickness on treatment outcomes following in vitro fertilization/intracytoplasmic sperm injection

 

Group A (≤8 mm)

Group B (9–14 mm)

Group C (≥15 mm)

p

NO.

464

7,539

1,525

 

Age (year)

30.44 ± 4.065

29.95 ± 4.367

30.07 ± 4.322

0.060

BMI (kg/m2)

21.3 ± 2.32

22.39 ± 3.07

22.33 ± 3.55

0.142

Duration of infertility (year)

3.64 ± 2.5

4.5 ± 3.62

4.6 ± 3.39

0.351

Basal FSH (IU/L)

7.76 ± 2.4

7.63 ± 2.71

7.79 ± 2.5

0.045

Gn (days)

12.09 ± 1.68

12.04 ± 1.64

12.10 ± 1.60

0.342

Gn dosage (IU)

2,163.21 ± 1,263.01

2,149.34 ± 876.44

2,156.46 ± 844.392

0.943

Type of Gn

 Recombinant FSH

83.78%(389)

86.99%(6,558)

87.60%(1,336)

0.101

 Urinary FSH

16.22%(75)

13.01%(981)

12.40%(189)

0.101

Endometrial pattern

 Triple line pattern

71.39%(331)

87.54%(6,599)

83.91%(1,279)

0.000

 No-triple line pattern

28.61%(133)

12.46%(940)

17.09%(246)

0.000

  IVF

81.03%(376)

77.99%(5,880)

76.19%(1,162)

0.096

  ICSI

18.96%(88)

22.01%(1,659)

23.81 (363)

0.096

 Long agonist protocol

100%(464)

100%(7,539)

100%(1,525)

NS

 No. of transferred embryos

2

2

2

NS

Infertility diagnosis

 Tubal factor

57.11%(265)

51.29%(3867)

42.29%(645)

0.000

 Male factor

28.23%(131)

38.49%(2902)

40.06%(611)

0.000

 Endometriosis, pelvic and uterine factors

5.38%(25)

5.50%(415)

5.83%(89)

0.865

 Unexplained and others

9.26%(43)

4.70%(355)

11.80%(180)

0.000

  1. Values are the mean ± SD unless otherwise noted
  2. BMI body mass index, FSH Follicle-stimulating hormone, Gn gonadotropin treatment, IVF in vitro fertilization, ICSI intracytoplasmic sperm injection, NS no significance